Back to database

Tesamorelin

Also known as: Egrifta, TH9507

Growth Hormone PeptidesFDA Approved (HIV lipodystrophy)Subcutaneous

A synthetic GHRH analog FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy. Also studied for cognitive benefits and NAFLD.

Molecular Weight

5135.9 Da

Half-Life

~26 minutes (but sustained GH elevation)

Sequence

Modified GHRH (1-44) with trans-3-hexenoic acid

Mechanism of Action

Stimulates pituitary GH release in a physiological pulsatile pattern. The trans-3-hexenoic acid modification improves receptor binding and stability.

Dosing Protocol

2mg subcutaneous daily, typically injected in the abdomen.

Open peptide calculator
Reconstitution

2mg vial + 2mL sterile water (provided with kit).

Storage

Lyophilized: room temperature. Reconstituted: use immediately or refrigerate.

Side Effects
  • ●Injection site reactions
  • ●Joint pain
  • ●Peripheral edema
  • ●Paresthesia
Key Research Findings
  • ●FDA-approved: reduced visceral adipose tissue by 15% in HIV patients
  • ●Improved cognitive function in older adults (GROW study)
  • ●Reduced liver fat in NAFLD pilot studies

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.